ION expands ETF trading capabilities with Tradeweb integration
Ilan Ganot, a director at Solid Biosciences Inc. (NASDAQ:SLDB), sold 3,278 shares of common stock on November 10, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $4.12, for a total value of $13,505. Prices for the sales ranged from $4.11 to $4.12.
Following the transaction, Ganot directly owns 95,412 shares of Solid Biosciences . This includes 91,370 shares held individually and 4,042 shares held jointly with Annie Ganot. Additionally, Ganot’s wife holds 14,839 shares, and the Ilan Ganot 2017 Irrevocable Trust holds 19,394 shares.
In other recent news, Solid Biosciences Inc. has announced significant developments regarding its investigational gene therapy for Duchenne muscular dystrophy, SGT-003. The therapy has received an Innovation Passport designation under the UK’s Innovative Licensing and Access Pathway (ILAP), providing an accelerated regulatory pathway in the UK. This designation allows the company to engage more effectively with regulators and utilize tools that expedite regulatory timelines. Additionally, Solid Biosciences has entered a non-exclusive worldwide license agreement with Kinea Bio for its AAV-SLB101 capsid, which will be used in Kinea Bio’s investigational gene therapy targeting dysferlinopathy.
Analyst firms have maintained positive outlooks on Solid Biosciences. Cantor Fitzgerald reiterated its Overweight rating with a $16.00 price target, emphasizing the novel capsid used in the company’s Duchenne muscular dystrophy program. Meanwhile, JMP Securities reiterated its Market Outperform rating with a $15.00 price target, noting progress in Solid Biosciences’ gene therapy programs for multiple conditions. These developments reflect ongoing advancements in the company’s therapeutic pipeline and strategic partnerships.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.